1.Rhabdomyolysis in a patient taking nebivolol.
Ye Jin KIM ; Hae Ri KIM ; Hong Jae JEON ; Hyun Jun JU ; Sarah CHUNG ; Dae Eun CHOI ; Kang Wook LEE ; Ki Ryang NA
Kidney Research and Clinical Practice 2016;35(3):182-186
β Blockers such as propranolol and labetalol are known to induce toxic myopathy because of their partial β₂ adrenoceptor agonistic effect. Nebivolol has the highest β1 receptor affinity among β blockers, and it has never been reported to induce rhabdomyolysis until now. We report a patient who developed rhabdomyolysis after changing medication to nebivolol. A 75-year-old woman was admitted to our hospital because of generalized weakness originating 2 weeks before visiting. Approximately 1 month before her admission, her medication was changed from carvedilol 12.5 mg to nebivolol 5 mg. Over this time span, she had no other lifestyle changes causing rhabdomyolysis. Her blood chemistry and whole body bone scan indicated rhabdomyolysis. We considered newly prescribed nebivolol as a causal agent. She was prescribed carvedilol 12.5 mg, which she was previously taking, instead of nebivolol. She was treated by hydration and urine alkalization. She had fully recovered and was discharged.
Aged
;
Chemistry
;
Female
;
Humans
;
Labetalol
;
Life Style
;
Muscular Diseases
;
Nebivolol*
;
Propranolol
;
Rhabdomyolysis*
2.Update on Newer Antihypertensive Medicines.
Journal of the Korean Medical Association 2010;53(8):717-722
The majority of hypertensive patients do not achieve target blood pressure for a variety of reasons, including insufficient medication, drug resistance, and noncompliance. There remains a significant need to develop new agents to better control hypertension. Nebivolol is a third-generation beta-adrenergic receptor blocker which is very highly cardioselective and has direct vasodilator properties via stimulation of endothelial nitric oxide synthase activity. Aliskiren is the first orally active inhibitor of renin as an antihypertensive agent. It is associated with dose-related falls in blood pressure comparable to other major classes of antihypertensive drugs with a placebo level of side effects. Endothelin is a powerful vasoconstrictor peptide. An endothelin-receptor antagonist such as bosentan significantly lowered blood pressure in patients with essential hypertension. Vasopeptidase inhibitors inhibit neutral endopeptidase and angiotensin converting enzymes, but side-effects such as angio-oedema and cough remain to be overcome. AngQb vaccine in hypertensive patients showed a marked reduction in early morning blood pressure without serious adverse events.
Amides
;
Angiotensins
;
Antihypertensive Agents
;
Benzopyrans
;
Blood Pressure
;
Cough
;
Drug Resistance
;
Endothelins
;
Ethanolamines
;
Fumarates
;
Humans
;
Hypertension
;
Nebivolol
;
Neprilysin
;
Nitric Oxide Synthase Type III
;
Renin
;
Sulfonamides
3.Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients.
Michael DOUMAS ; Alexandros TSAKIRIS ; Stella DOUMA ; Alkiviadis GRIGORAKIS ; Angelos PAPADOPOULOS ; Athina HOUNTA ; Sotirios TSIODRAS ; Dimitrios DIMITRIOU ; Helen GIAMARELLOU
Asian Journal of Andrology 2006;8(2):177-182
AIMTo investigate the effect of substituting beta-blockers with nebivolol on the erectile function of patients suffering from essential hypertension.
METHODSForty-four young and middle-aged men (31-65 years) with essential hypertension visited our outpatient clinic and took beta-blocker treatment (atenolol, metoprolol or bisoprolol) for more than 6 months. All the patients completed a questionnaire regarding erectile function (International Index for Erectile Function). Patients were then switched to an equipotent dose of nebivolol for 3 months and, at the end of this time period, filled out the same questionnaire.
RESULTSTwenty-nine out of the 44 (65.9%) patients who took beta-blockers (atenolol, metoprolol or bisoprolol) had exhibited erectile dysfunction (ED). Their systolic and diastolic blood pressure did not change significantly with the treatment switch. In 20 out of these 29 (69%) patients, a significant improvement in the erectile function score was exhibited after 3 months of nebivolol administration, and in 11 of these 20 patients, erectile function was normalized.
CONCLUSIONNebivolol seems to have a beneficial effect on ED (possibly due to increased nitric oxide availability); however, further prospective, randomized, placebo-controlled studies are needed to confirm the beneficial effects of nebivolol.
Adrenergic beta-Antagonists ; adverse effects ; therapeutic use ; Adult ; Aged ; Antihypertensive Agents ; adverse effects ; Benzopyrans ; therapeutic use ; Erectile Dysfunction ; chemically induced ; drug therapy ; Ethanolamines ; therapeutic use ; Humans ; Hypertension ; complications ; Male ; Middle Aged ; Nebivolol ; Surveys and Questionnaires